Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 4/20 | 0.42 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.42 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.33 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10482167 | 0.98 | GABRA1 (0.43) | GABRA1GABRB2TAAR1HTR1ASLC9A1 | |
| Bromide SCHEMBL7082953 | 0.96 | GABRA1 (0.42) | GABRA1GABRB2TAAR1HTR1ASLC9A1 | |
| SCHEMBL11081926 | 0.83 | GABRA1 (0.43) | GABRA1GABRB2TAAR1HTR1ASLC9A1 | |
| Hydrochloric Acid SCHEMBL28418842 | 0.83 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL30498855 | 0.83 | GABRA1 (0.43) | GABRA1GABRB2TAAR1HTR1ASLC9A1 | |
| Hydrochloric Acid SCHEMBL77688 | 0.82 | GABRA1 (0.41) | GABRA1GABRB2ALDH1A1MAPTIDO1 | |
| SCHEMBL23044955 | 0.81 | GABRA1 (0.45) | GABRA1GABRB2TAAR1HTR1ASLC9A1 | |
| SCHEMBL6573497 | 0.80 | LIPG (0.41) | KCNH2 | |
| SCHEMBL27231396 | 0.80 | LIPG (0.41) | KCNH2 | |
| SCHEMBL643737 | 0.80 | GABRA1 (0.43) | GABRA1GABRB2ALDH1A1MAPTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108395522-B | Epoxy acrylic resin with four functionalities and preparation method and application thereof | 广州市嵩达新材料科技有限公司 | 2020-05-19 | — | — | CN | claimed |
| CN-108997247-A | A kind of preparation method of Rivaroxaban intermediate | 泰州申合泰尔生物医药有限公司 | 2018-12-14 | — | — | CN | claimed |
| CN-108892663-A | A kind of intermediate, preparation method and use synthesizing razaxaban | 泰州申合泰尔生物医药有限公司 | 2018-11-27 | — | — | CN | claimed |
| CN-1226293-C | Preparation method of 2- (2-hydroxyphenyl) -2H-benzotriazole | LG CHEMICAL LTD (KR) | 2005-11-09 | — | — | CN | claimed |
| CN-1455773-A | Method for preparing 2-(2-hydroxyphenyl)-2h-benzotriazole | LG CHEMICAL LTD (KR) | 2003-11-12 | — | — | CN | claimed |
| EP-1351944-A1 | METHOD FOR PREPARING 2-(2-HYDROXYPHENYL)-2H-BENZOTRIAZOLE | LG Chem Ltd. (KR) | 2003-10-15 | — | — | EP | claimed |
| US-6559316-B2 | Reacting o-nitrophenylazohydroxyphenyl compound with hydrazine hydrate; reduction in presence of water, zinc powder, and sulfuric acid with/without phase transfer catalyst | LG CHEM, LTD. (KR) | 2003-05-06 | — | — | US | claimed |
| US-20030050480-A1 | METHOD FOR PREPARING 2-(2-HYRDROXYPHENYL)-2H-BENZOTRIAZOLE | LG CHEM, LTD. (KR) | 2003-03-13 | — | — | US | claimed |
| WO-2002055508-A1 | METHOD FOR PREPARING 2-(2-HYDROXYPHENYL)-2H-BENZOTRIAZOLE | LG CHEM, LTD. (KR) | 2002-07-18 | — | — | WO | claimed |
| US-20240301168-A1 | CURABLE COMPOSITION, CURED OBJECT, FIBER-REINFORCED COMPOSITE MATERIAL, AND MOLDED FIBER-REINFORCED RESIN ARTICLE | DIC CORPORATION (JP) | 2024-09-12 | — | — | US | disclosed |
| EP-4339220-A1 | CURABLE COMPOSITION, CURED OBJECT, FIBER-REINFORCED COMPOSITE MATERIAL, AND MOLDED FIBER-REINFORCED RESIN ARTICLE | DIC Corporation (JP) | 2024-03-20 | — | — | EP | disclosed |
| CN-117043221-A | Curable composition, cured product, fiber-reinforced composite material, and fiber-reinforced resin molded article | DIC株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-3551188-B1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RES INST (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2023-09-12 | — | — | US | disclosed |
| EP-0822545-A2 | Optical component and spirobiindan polymer therefor | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1998-02-04 | — | — | EP | disclosed |
| EP-0354789-B1 | High energy beam-sensitive copolymer | SOMAR CORP (JP) | 1994-06-01 | — | — | EP | disclosed |
| US-5015558-A | Photoresists sensitive to high energy beams | SOMAR CORPORATION (JP) | 1991-05-14 | — | — | US | disclosed |
| EP-0354789-A2 | High energy beam-sensitive copolymer | SOMAR CORPORATION (JP) | 1990-02-14 | — | — | EP | disclosed |
| US-4874859-A | CROSSLINKING AGENT | SOCIETE CHIMIQUE DES CHARBONNAGES (FR) | 1989-10-17 | — | — | US | disclosed |
| US-4277490-A | Insecticidal 1-(2-naphthyl)-cyclobutane carboxylate | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050480-A1 | METHOD FOR PREPARING 2-(2-HYRDROXYPHENYL)-2H-BENZOTRIAZOLE | CYP8B1, CYP4Z1, CBR1 | GABRA1 1120/4885GABRB2 1696/4885HTR1A 549/4885 |
| US-11752153-B2 | Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors | TXN, TXNL1, TXN2 | GABRA1 4165/4885GABRB2 3623/4885HTR1A 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.